Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07277231 · ClinicalTrials.gov registry record · Phase 3
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
A Phase 3 study, sponsored by BeOne Medicines.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 500
- Enrollment target
NCT07277231 is a Phase 3 study that is actively recruiting participants, run by BeOne Medicines. The registered enrollment target is 500 participants.
The verdict
NCT07277231, a Phase 3 study, is actively recruiting participants, sponsored by BeOne Medicines.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 500 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the efficacy and safety of fixed-duration sonrotoclax (also known as BGB-11417) plus zanubrutinib (also known as BGB-3111) (SZ) compared with fixed-duration of venetoclax plus acalabrutinib (AV) in participants with previously untreated chronic lymphocytic leukemia (CLL).
Interventions
- DRUG Zanubrutinib
- DRUG Venetoclax
- DRUG Sonrotoclax
- DRUG Acalabrutinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2026-01-22 |
| Est. Completion | 2031-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07277231
The ClinicalTrials.gov registry entry for NCT07277231 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BeOne Medicines, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Zanubrutinib is the first listed.
NCT07277231 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07277231 about?
NCT07277231 is a clinical study titled "A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia". The purpose of this study is to investigate the efficacy and safety of fixed-duration sonrotoclax (also known as BGB-11417) plus zanubrutinib (also known as BGB-3111) (SZ) compared with fixed-duration of venetoclax plus acalabrutinib (AV) in participants with previously untreated chronic lymphocytic...
What is the current status of trial NCT07277231?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 500 participants. The study started on 2026-01-22. Estimated completion is 2031-11.
What interventions are being tested in trial NCT07277231?
The interventions under investigation include: Zanubrutinib (DRUG), Venetoclax (DRUG), Sonrotoclax (DRUG), Acalabrutinib (DRUG).
Who is sponsoring clinical trial NCT07277231?
This trial is sponsored by BeOne Medicines, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.